WO2008024422A2 - Procédés et compositions de décontamination et de traitement de maladie ou de lésion - Google Patents

Procédés et compositions de décontamination et de traitement de maladie ou de lésion Download PDF

Info

Publication number
WO2008024422A2
WO2008024422A2 PCT/US2007/018604 US2007018604W WO2008024422A2 WO 2008024422 A2 WO2008024422 A2 WO 2008024422A2 US 2007018604 W US2007018604 W US 2007018604W WO 2008024422 A2 WO2008024422 A2 WO 2008024422A2
Authority
WO
WIPO (PCT)
Prior art keywords
transition metal
acid
alloy
peroxygen
alcohol
Prior art date
Application number
PCT/US2007/018604
Other languages
English (en)
Other versions
WO2008024422A3 (fr
Inventor
Daryl J. Tichy
Brian G. Larson
Original Assignee
Solutions Biomed, Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US11/510,133 external-priority patent/US7504369B2/en
Priority claimed from US11/514,722 external-priority patent/US7553805B2/en
Application filed by Solutions Biomed, Llc filed Critical Solutions Biomed, Llc
Publication of WO2008024422A2 publication Critical patent/WO2008024422A2/fr
Publication of WO2008024422A3 publication Critical patent/WO2008024422A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2/00—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor
    • A61L2/16—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor using chemical substances
    • A61L2/18—Liquid substances or solutions comprising solids or dissolved gases
    • A61L2/186—Peroxide solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/242—Gold; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/30—Zinc; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/32—Manganese; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/34—Copper; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/40—Peroxides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A62—LIFE-SAVING; FIRE-FIGHTING
    • A62D—CHEMICAL MEANS FOR EXTINGUISHING FIRES OR FOR COMBATING OR PROTECTING AGAINST HARMFUL CHEMICAL AGENTS; CHEMICAL MATERIALS FOR USE IN BREATHING APPARATUS
    • A62D3/00—Processes for making harmful chemical substances harmless or less harmful, by effecting a chemical change in the substances
    • A62D3/30—Processes for making harmful chemical substances harmless or less harmful, by effecting a chemical change in the substances by reacting with chemical agents
    • A62D3/38—Processes for making harmful chemical substances harmless or less harmful, by effecting a chemical change in the substances by reacting with chemical agents by oxidation; by combustion
    • A—HUMAN NECESSITIES
    • A62—LIFE-SAVING; FIRE-FIGHTING
    • A62D—CHEMICAL MEANS FOR EXTINGUISHING FIRES OR FOR COMBATING OR PROTECTING AGAINST HARMFUL CHEMICAL AGENTS; CHEMICAL MATERIALS FOR USE IN BREATHING APPARATUS
    • A62D2101/00—Harmful chemical substances made harmless, or less harmful, by effecting chemical change
    • A62D2101/02—Chemical warfare substances, e.g. cholinesterase inhibitors
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Definitions

  • the present invention is .drawn to therapeutic aqueous compositions which are useful in treating a variety of diseases or injuries including cancer, bacterial disease and infection, viral disease and infection, injuries caused by chemical and/or biological warfare, and fungal and yeast disease and infection as well as decontaminating surfaces which have been contacted by any agent or pathogen which might cause such a disease.
  • a method for decontaminating a surface contaminated with a chemical or biological warfare agent can comprise contacting said surface with an effective amount of a composition.
  • the composition includes an aqueous vehicle with water and from 0.001 wt% to 40.0 wt% of a peroxygen.
  • the composition further includes from 0.001 ppm to 50,000 ppm by weight of a transition metal or alloy thereof based on the aqueous vehicle content.
  • a method of treating a subject for viral infection can comprise administering an aqueous composition to the subject in an amount sufficient to prevent or treat the viral infection.
  • a method of treating a subject for bacterial infection can comprise administering an aqueous composition to the subject in an amount sufficient to prevent or treat the bacterial infection.
  • a method of treating a subject for fungal infection can comprise administering an aqueous composition to the subject in an amount sufficient to prevent or treat the fungal infection.
  • the composition can comprise an aqueous vehicle, including water, from 0.0001 wt% to 10.0 wt% of a peroxygen, and optionally, an alcohol. From 0.0001 ppm to 50,000 ppm by weight of a transition metal or alloy thereof based on the aqueous vehicle content can also be present.
  • a method for treating cancerous tissue in a subject includes administering to the subject afflicted with the cancerous tissue a therapeutically effective amount of an aqueous composition.
  • the composition includes an aqueous vehicle with water; from 0.0001 wt% to 10.0 wt% of a peroxygen; and optionally, an alcohol.
  • the composition further includes from 0.0001 ppm to 50,000 ppm by weight of a transition metal or alloy thereof based on the aqueous composition content. Additional features and advantages of the invention will be apparent from the detailed description that follows, which illustrates, by way of example, features of the invention.
  • decontaminate does not require that complete decontamination occur. In other words, partial decontamination to complete decontamination are included whenever the term "decontaminate,” “decontaminating,” “decontamination,” etc. is used.
  • disinfect is used to include not only fighting o infection of virus, bacteria, or other living organisms that may be used for biological warfare, but also includes decontamination of surfaces that are exposed to harmful chemicals often used in chemical warfare, such as by oxidation of the chemical. Again, complete disinfection is not required for disinfection to occur. Generally, though sanitizers, sterilants and disinfectants are used for the same purpose, i.e.
  • a sterilant composition exhibits a greater kill level compared to a disinfectant, which in turn has a better kill level than a sanitizer.
  • a disinfectant most applications require only sanitizer or disinfectant levels bacteria/virus reduction, though other applications benefit considerably from the use of sterilants.
  • the term "disinfectant" is used generally to refer to each of sanitizers, disinfectants, and sterilants unless the context clearly dictates otherwise.
  • solution is also used throughout the specification to describe the liquid compositions of the present invention.
  • solutions include colloidal transition metals, these compositions can also be described as dispersions or suspensions.
  • the continuous phase is typically a solution, and the transition metal is present as a colloid, for convenience, these compositions will typically be referred to as “solutions" herein
  • compositions of the present invention refers to the total absence of or near total absence of a specific compound or composition.
  • substantially free when used with regard to the compositions of the present invention refers to the total absence of or near total absence of a specific compound or composition.
  • a composition is said to be substantially free of aldehydes, there are either no aldehydes in the composition or only trace amounts of aldehydes in the composition.
  • peroxygen refers to any compound containing a dioxygen (O- O) bond. Dioxygen bonds, particularly bivalent O-O bonds, are readily cleavable thereby allowing compounds containing them to act as powerful oxidizers.
  • Non- limiting examples of classes of peroxygen compounds include peracids, peracid salts, and peroxides, such as hydrogen peroxide.
  • biological warfare agent and "biological weapon” are interchangeable and refer to any biological organism or toxin that are often used as a weapon of war or terrorism to kill, injure, or incapacitate.
  • chemical warfare agent or “chemical weapon” refers to chemical agents which have toxic properties and can be used in war or terrorism to kill, injure, or incapacitate.
  • colloidal or metallic particles can be in the form of composites of multiple metals, or alloys can also include co-dispersions of multiple metals as separate particles.
  • subject refers to any animal.
  • subjects can be mammals, and more particularly humans.
  • a weight ratio range of about 1 wt% to about 20 wt% should be interpreted to include not only the explicitly recited limits of 1 wt% and about 20 wt%, but also to include individual weights such as 2 wt%, 11 wt%, 14 wt%, and sub-ranges such as 10 wt% to 20 wt%, 5 wt% to 15 wt%, etc.
  • a method involves contacting the contaminated surface with a composition comprising an aqueous vehicle, including water and from 0.001 wt% to 30.0 wt% of a peroxygen. Additionally, from 0.001 ppm to 50,000 ppm by weight of a transition metal based on the aqueous vehicle content can also be present. In one embodiment the
  • the invention provides a method for treating subjects afflicted with or at risk of obtaining a viral infection by administering a therapeutic aqueous composition containing a peroxygen, a transition metal, and optionally, an alcohol.
  • the invention provides a method for treating subjects afflicted with or at risk of obtaining a bacterial infection by administering a therapeutic aqueous composition containing a peroxygen, a transition metal, and optionally, an alcohol.
  • the invention provides a method for treating subjects afflicted with or at risk of obtaining a fungal infection by administering a therapeutic aqueous composition containing a peroxygen, a transition metal, and optionally, an alcohol.
  • the invention provides a method for treating subjects having cancerous tissue by administering a therapeutic aqueous composition containing a peroxygen, a transition metal, and optionally, an alcohol.
  • the lower end of the range of the peroxygen can be modified to 0.0001 wt%, 0.05 wt%, and 0.1 wt% and/or the upper end of the range can be modified to 40 wt%, 30 wt%, 20 wt%, 10 wt%, 5 wt%, 3 wt%, or 1.5 wt% in accordance with specific embodiments of the present invention.
  • the concentration of the metal content can also be modified to 10 ppm, 1 ppm, 0.1 ppm, or 0.001 ppm by weight at the lower end of the range, and/or to 50,000, 20,000 ppm, 10,000 ppm, 5000 ppm, or 1500 ppm by weight at the upper end of the range.
  • these ranges are merely exemplary, one skilled in the art could modify these ranges for a particular application, considering such things as the type of alcohol (polyhydric, food grade, mixtures, etc.); the type of peroxygen (peroxide, peracid, combination of peroxide/peracid, etc.); and the type of metal (ionic, colloidal, alloy, etc.).
  • peracid in treating a human for exposure to biological or chemical agents, lower amounts of peracid may be used so as to be within safe parameters, whereas when decontaminating terra firma, facilities, or equipment, higher concentrations of the peracid may be useable (closer to the 40 wt%).
  • hydrogen peroxide is used as the peroxygen compound, then a broader range of the material may be useable for a wider range of applications. It is noted that any combination of these upper and lower limits for each of the ingredients are included herein.
  • the aqueous vehicle can optionally include other ingredients, such as organic co-solvents, so long as the additional ingredients are compatible with the intended use.
  • additional ingredients should be biologically safe or present only in limited biologically safe amounts.
  • an alcohol can be present at from 0.05 wt% to 40 wt%, with the lower end of the range of the alcohol being modifiable to 0.05 wt% or 0.1 wt%, and the upper end of the range being modifiable to 30 wt%, 20 wt% or 10 wt% in accordance with specific embodiments of the present invention..
  • alcohols including aliphatic alcohols and other carbon-containing alcohols, having from 1 to 24 carbons (Ci-C 2 4 alcohol) can be used.
  • C1-C24 alcohol does not necessarily imply only straight chain saturated aliphatic alcohols, as other carbon-containing alcohols can also be used within this definition, including branched aliphatic alcohols, alicyclic alcohols, aromatic alcohols, unsaturated alcohols, as well as substituted aliphatic, alicyclic, aromatic, and unsaturated alcohols, etc.
  • the aliphatic alcohols can be C 1 to C 5 alcohols including methanol, ethanol, propanol and isopropanol, butanols, and pentanols, due to their availability and lower boiling points.
  • polyhydric alcohols can also be used effectively in enhancing the disinfectant and sterilant potency of the compositions of the present invention, as well as provide some degree of added stabilization.
  • examples of polyhydric alcohols which can be used in the present invention include but are not limited to ethylene glycol (ethane-1 ,2-diol) glycerin (or glycerol, propane-1,2,3-triol), and propane-1 ,2-diol.
  • non-aliphatic alcohols may also be used including but not limited to phenols and substituted phenols, erucyl alcohol, ricinolyl alcohol, arachidyl alcohol, capryl alcohol, capric alcohol, behenyl alcohol, lauryl alcohol (1-dodecanol), myristyl alcohol (1-tetradecanol), cetyl (or palmityl) alcohol (1-hexadecanol), stearyl alcohol (1-octadecanol), isostearyl alcohol, oleyl alcohol (cis-9-octadecen-1-ol), palmitoleyl alcohol, linoleyl alcohol (9Z, 12Z-octadecadien-1-ol), elaidyl alcohol (9E-octadecen-1-ol), elaidolinoleyl alcohol (9E 1 12E-octadecadien-1-ol), linolenyl alcohol (9Z, 12Z, 15
  • methanol, ethanol, and denatured alcohols can often be preferred for use because of their availability and cost.
  • Glycerol is also preferable for use in some embodiments. If the desire is to provide a food grade composition, as may be desirable for mucosal, skin, or alimentary canal application, then alcohols can be selected that satisfy this requirement. As these ranges are merely exemplary, one skilled in the art could modify these ranges for a particular application, considering such things as whether alcohol selected for use is polyhydric, whether the alcohol is food grade, mixtures of alcohols, etc.
  • the metal in accordance with the embodiments of the present invention, can be in ionic form (e.g. a metal salt) and/or colloidal form.
  • the transition metal can be in a sub- micron form (i.e. dispersion of less than 1 ⁇ m metal colloidal particles).
  • larger colloidal transition metal particles can also be used in certain applications.
  • Typical transition metals that are desirable for use include Group Vl to Group Xl transition metals, and more preferably, can include Group X to Group Xl transition metals. Alloys including at least one metal from the Group Vl to Group Xl metals can also be used.
  • colloidal metals typically, the surface is usually more susceptible to such oxidation.
  • colloidal metals when colloidal metals are dispersed in a colloidal solution, there is often an amount of the metal in ionic or salt form that is also present in the suspension solution.
  • colloidal silver may include a certain percentage of a silver salt or ionic silver in solution, e.g., 10% to 90% by weight of metal content can be ionic based on the total metal content.
  • certain preferred metals for use in accordance with embodiments of the present invention are ruthenium, rhodium, osmium, iridium, palladium, platinum, copper, gold, silver, alloys thereof, and mixtures thereof. Silver is often the most preferred, depending on the application, the levels of kill that are desired or required, the type of pathogen being targeted, the area of the body or substrate that is being cleaned or disinfected, etc.
  • any of these embodiments can also benefit from the use of alloys.
  • certain combinations of metals in an alloy may provide an acceptable kill level for a specific pathogen, and also provide benefits that are related more to secondary consideration, such as solution stability, substrate to be cleaned, etc.
  • Preferred examples of transition metal alloys for use in the present invention include but are not limited to copper-silver allows, silver-manganese alloys, Iron- copper alloys, chromium-silver alloys, gold-silver alloys, and magnesium-silver alloys.
  • colloidal silvers that can be used include those sold by Solutions IE, Inc. under the trade names CS Plus and C S Ultra.
  • Other colloidal silver products that can be used as the silver source include ASAP 1 Sovereign Silver, Silver Max, and the like.
  • preferred silver salts include but are not limited to silver nitrate, silver acetate, silver citrate, silver oxide, and silver carbonate.
  • the colloidal particles used in the present invention can have a particle size range of from 0.0001 ⁇ m to 1.0 ⁇ m.
  • the colloidal transition metal particles can have a size range of from 0.030 ⁇ m to 0.5 ⁇ m.
  • the average particle size is 0.35 ⁇ m to 0.45 ⁇ m.
  • any colloidal silver solution that is functional for use in the formulations of the present invention can be used, in one embodiment, it can be desirable to use RO water as the suspension medium for the colloidal silver that is mixed with the other ingredients.
  • the RO water can also be distilled, resulting in 18-20 M ⁇ water, though this is not required.
  • the peroxygen component of the disinfectant solution can be a single compound or a combination of multiple peroxygen compounds or peroxygen forming compounds.
  • the peroxygen portion of the disinfectant formulation can range from about 0.0001 wt% to about 40.0 wt%. In one embodiment the range can be from 0.05 wt% to 30.0 wt%. In another embodiment the range can be from 0.1 to 20 wt%. In yet another embodiment the range can be from 0.5 wt% to 10 wt%. In yet another embodiment, the range can be from .0001wt% to 10 wt%. In another embodiment, the range can be from .05 wt% to 5 wt%. In yet a further embodiment, the range can be from 0.1 to 1.5 wt%
  • the peroxygen can be any aliphatic or aromatic peracid (or peroxyacid) that is functional for disinfectant purposes in accordance with embodiments of the present invention. While any functional peroxyacid could be used, peroxyacids containing from 1 to 7 carbons are the most practical for use. These peroxyacids can include, but not be limited to, peroxyformic acid, peroxyacetic acid, peroxyoxalic acid, peroxypropanoic acid, perlactic acid, peroxybutanoic acid, peroxypentanoic acid, peroxyhexanoic acid, peroxyadipic acid, peroxycitric, and/or peroxybenzoic acid and mixtures thereof.
  • any peracid component of the peroxygen not be present so as to reach the upper limits of the peroxygen component.
  • Such amounts of peracids can render the aqueous composition unsafe for biological use.
  • one skilled in the art would readily be able to determine biologically safe amounts for any peracid used, and total amounts of peracid components used in the aqueous composition.
  • the peroxyacid used in the aqueous component of the formulations of the present invention can be prepared using any method known in the art.
  • the resultant mixture contains both the peroxyacid and the corresponding acid that it is prepared from.
  • the presence of the related acid acetic acid provides stability to the mixture, as the reaction is an equilibrium between the acid, hydrogen peroxide, and the peroxyacid and water, as follows:
  • Peracid salts such as salts of the above listed peracids, can also be included in peroxygen component of the disinfectant solutions.
  • Non-limiting examples of such salts include permanganates, perborates, perchlorates, peracetates, percarbonates, persulphates, and the like.
  • the salts can be used alone or in combination with each other or other peroxygen compounds to form the peroxygen component of the invention.
  • the peroxygen component of the invention can include a peroxide compound. While hydrogen peroxide is considered to be desirable peroxide for use in accordance with embodiments of the present invention, other peroxides can also be used, such as metal peroxides and peroxyhydrates.
  • the metal peroxides that can be used include, but are not limited to, sodium peroxide, magnesium peroxide, calcium peroxide, barium peroxide, and/or strontium peroxide.
  • Other salts for example sodium percarbonate
  • peroxides when used in the peroxygen component of the present invention they are used in combination with other non-peroxide peroxygen compounds, e.g. peracids.
  • the peroxides can be used alone or in combination with other peroxygen compounds to form the peroxygen component of the present invention.
  • biologically safe amounts of peroxides could be readily determined by one ordinary skill in the art.
  • aqueous compositions used in the methods of the present invention can be incorporated with other ingredients to form a variety of products for administration including but not limited to ointments, creams, mouth rinses, gels, lozenges or gums for application to the mouth and throat, wipes for skin application, dermal patches, foams, powders and aerosols for topical or inhalation application, bandage dressings, etc.
  • therapeutic aqueous compositions of the present invention can be formulated into a gel, foam, cream, spray, or ointment for topical application.
  • the composition can include other excipients and fillers such gelling or thickening agents.
  • gelling or thickening agents include but are not limited to natural gum such as guar and guar derivatives, a synthetic polymer, a clay, an oil, a wax, aloe vera gel, an acrylate homopolymer, an acrylate copolymer, a carbomer, cellulose, a cellulose derivative, algin, an algin derivative, a water-insoluble Ca-C-20 alcohol, carrageenan, fumed silica, mixtures thereof, and the like.
  • Other excipients common to cream, gel and ointment formulations may also be included. Such excipients and their use are well known to those of ordinary skill in the art.
  • the ointment, gel or cream formulation can be useful in treating both bacterial and viral caused skin infections as well as acting prophylactically to prevent bacterial infection.
  • the composition can be used as a liquid dispersion bath for dipping instruments or other objects, as a spray for applying to less mobile objects, as a wipe where the liquid dispersion is applied to a fabric or fabric-like material for easy application without the need for spray or other application methods, as a topical dressing, as a mouthwash, etc.
  • any application method known by those skilled in the art can be utilized in accordance with embodiments of the present invention.
  • the composition can contact the contaminated surface by spraying.
  • the composition can contact the contaminated surface by wiping.
  • the composition can contact the contaminated surface by submersion in the composition.
  • the composition can contact the contaminated surface by pouring or splashing.
  • the mode of administration can be dependent on the disease or infection being treated and the formulated potency of the therapeutic aqueous composition. For example, when a bacterial skin infection is treated, it may be desirable to use topical administration of the aqueous composition, whereas, when an internal or subcutaneous tumor is the intended treatment target, injection or oral administration may be a desired mode of administration.
  • this composition can be used against a wide variety of pathogens, biological agents, and chemical with relative to complete safety to humans and other mammals.
  • biological agents which the composition can be used for include but are not limited to those which cause anthrax, ebola, bubonic plague, cholera, tularemia, brucellosis, Q fever, machupo, coccidioides mycosis, glanders, melioidosis, shigella, rocky mountain spotted fever, typhus, psittacosis, yellow fever, Japanese B encephalitis, rift valley fever, and/or smallpox.
  • Examples of chemical warfare agents which the composition can be used for include but are not limited to tabun, sarin, soman, cyclohexyl methylphosphonofluoridate, VX, mustard agent (gas), hydrogen cyanide, arsines, phencyclidine, ricin, abrin, and/or agent 15.
  • the present invention also provides methods of treating (including prophylactically treating) viral infections, bacterial infections, or cancerous tissue.
  • viral infections which may be treated using the methods of the present invention include, without limitation, molluscum contagiosum infection, HTLV infection, HTLV-1 infection, HIV/AIDS infection, human papillomavirus infection, herpesvirus infection, genital herpes infection, viral dysentery, flu, measles, rubella, chickenpox, mumps, polio, rabies, mononucleosis, ebola, respiratory syncytial virus, dengue fever, yellow fever, lassa fever, arena virus, bunyavirus, filovirus, flavivirus, hantavirus, rotavirus, viral meningitis, west Nile fever, arbovirus, parainfluenza, smallpox, epstein-barr virus, dengue hemorrhagic fever, cytomegalovirus, infant cytomegalic virus, progressive multif
  • bacterial infections which can be treated and prevented using the methods of the present invention include, without limitation, e. coli infections (e.g.
  • Yersinia pestis pneumonic plague
  • staphyloccal infection streptococcal infection
  • mycobacteria infection bacterial pneumonia, snigella dysentery, serrate infection
  • Candida infection cryptococcal infection, and the like.
  • Other specific examples include methicillin resistant staphylococcus aureus, anthrax, or tuberculosis.
  • fungal infection examples include thrush, candidiasis, cryptococcosis, histoplasmosis, blastomycosis, aspergillosis, coccidioidomycosis, paracoccidiomycosis, sporotrichosis, zygomycosis, chromoblastomycosis, lobomycosis, mycetoma, onychomycosis, piedra pityriasis versicolor, tinea barbae, tinea capitis, tinea corporis, tinea cruris, tinea favosa, tinea nigra, tinea pedis, otomycosis, phaeohyphomycosis, or rhinosporidiosis.
  • Yeast infections can also be treated and prevented.
  • the present invention also provides methods for treating cancerous tissue in a subject.
  • the present invention has been shown to be effective at reducing the size of and even eliminating cancerous tumors.
  • the types of cancers which can be treated using the methods of the present invention include, without limitation, breast cancer, prostate cancer, lung and/or bronchus cancers, colon and rectum cancers, urinary bladder cancer, melanomas of the skin, pancreatic cancer, ovarian cancer, thyroid cancer, stomach cancer, brain cancer, cervical cancer, testicular cancer, lymphomas, cancers of the blood, cancer of the bones and joints, and the like.
  • the amounts of the therapeutic aqueous compositions which can be administered to treat disease or injury using the methods of the present invention can vary depending on the type and location of the targeted infection, the mode of administration, and the potency or concentration of the aqueous composition administered. For example, when administered topically using a spray or submersion administration mode for topical local effect, the amount of aqueous composition may not be as important, but rather, the concentration of the aqueous composition and the frequency of administration may be more significant.
  • the administration can occur one or more times daily for a period of 1 day to 180 days. In another embodiment, the administration can occur one or more times daily for a period of 1 to 7 days. In another embodiment, the administration can occur one or more times for a period of 4 hours to 24 hours.
  • the types of surfaces which can be sterilized or decontaminated under the present invention are wide ranging.
  • Non-limiting examples of types of surfaces include skin, hair, mucosal tissue, alimentary canal tissue, metals, fabrics, plastics, glass, composites, woods, and terra firma.
  • the surfaces can be smooth or porous, although some application or contacting methods may be more effective with certain surface types.
  • An aqueous disinfectant composition is prepared in accordance with embodiments of the present invention, which includes the following ingredients in approximate amounts: 9 wt% ethanol; 1.3 wt% peroxyacetic acid (from a 6 wt% solution); less than 3 wt% hydrogen peroxide to stabilize the peroxyacetic acid; and the balance being water containing 600 ppm colloidal silver. It is noted that there will be less than 600 ppm by weight of the colloidal silver when based on the aqueous vehicle content as a whole.
  • An aqueous disinfectant composition is prepared in accordance with embodiments of the present invention, which includes the following ingredients in approximate amounts: 9 wt% isopropanol; 1.3 wt% peroxypropanoic acid (from a 6 wt% solution); less than 3 wt% of a peroxide, e.g., sodium peroxide, to stabilize the peroxypropanoic acid; and the balance being water containing 600 ppm ionic silver. It is noted that there will be less than 600 ppm by weight of the ionic silver when based on the aqueous vehicle content as a whole.
  • An aqueous disinfectant composition is prepared in accordance with embodiments of the present invention, which includes the following ingredients in approximate amounts: 20 wt% denatured alcohol; 5 wt% peroxyformic acid; and the balance being water containing 10,000 ppm by weight colloidal silver and copper alloy. Small amounts of hydrogen peroxide and formic acid are also added to the composition as a whole to stabilize the peroxyformic acid. It is noted that there will be less than 10,000 ppm by weight of the colloidal silver when based on the aqueous vehicle content as a whole.
  • An aqueous disinfectant composition is prepared in accordance with embodiments of the present invention, which includes the following ingredients in approximate amounts: 9 wt% ethanol; 1.3 wt% peroxyacetic acid (from a 6 wt% solution); less than 3 wt% hydrogen peroxide to stabilize the peroxyacetic acid; and the balance being water containing 80 ppm colloidal silver. It is noted that there will be less than 80 ppm by weight of the colloidal silver when based on the aqueous vehicle content as a whole.
  • An aqueous disinfectant composition is prepared in accordance with embodiments of the present invention, which includes the following ingredients in approximate amounts: 10 wt% glycerol; 1.3 wt% peracetic acid; and the balanced being water with approximately 300 ppm colloidal silver. It is noted that there will be less than 300 ppm by weight of the colloidal silver when based on the aqueous vehicle content as a whole.
  • An aqueous disinfectant composition is prepared in accordance with embodiments of the present invention, which includes the following ingredients in approximate amounts: 10.0 wt% glycerol; 1.8 wt% percitric acid; and the balance being water with approximately 300 ppm colloidal silver. It is noted that there will be less than 300 ppm by weight of the colloidal silver when based on the aqueous vehicle content as a whole.
  • An aqueous disinfectant composition is prepared in accordance with embodiments of the present invention, which includes the following ingredients in approximate amounts: 8.5 wt% 1-propanol; 1.3 wt% peracetic acid; and the balance being RO water (reverse osmosis water) containing about 300 ppm by weight colloidal silver. It is noted that there will be less than 300 ppm by weight of the colloidal silver when based on the aqueous vehicle content as a whole.
  • An aqueous disinfectant composition is prepared in accordance with embodiments of the present invention, which includes the following ingredients in approximate amounts: 40 wt% glycerol; 8 wt% percitric acid; and the balance being RO water (reverse osmosis water) containing about 300 ppm by weight colloidal silver. It is noted that there will be less than 300 ppm by weight of the colloidal silver when based on the aqueous vehicle content as a whole.
  • An aqueous disinfectant composition is prepared in accordance with embodiments of the present invention, which includes the following ingredients in approximate amounts: 8.5 wt% glycerol; 0.4 wt% peracetic acid; and the balance being RO water (reverse osmosis water) containing 300 ppm by weight colloidal silver. It is noted that there will be less than 300 ppm by weight of the colloidal silver when based on the aqueous vehicle content as a whole.
  • Example 10 Kill-time studies of Staphylococcus aureus using disinfectant of Example 1
  • test suspension was prepared by growing a 5 ml culture of Staphylococcus aureus, ATCC 6538, in Todd Hewitt Broth at 37°C, for 20 hours. Five (5) ml of culture was pelleted by centrifugation, washed with 5 ml sterile 18 M ⁇ water, centrifuged again, and resuspended in a final volume of 5 ml sterile water.
  • a neutralizer was prepared that consisted of 9 ml tubes of 12.7 wt% Tween 80 (surfactant), 6.0 wt% Tamol, 1.7 wt% lecithin, 1 wt% peptone, and 0.1 wt% cystine, to which was added 10 pd of catalase solution (Sigma, C100, 42,300 units/mg).
  • the "Kill Time” procedure followed was as follows: A 9.9 ml aliquot of the disinfectant of Example 1 (containing 5% v/v horse serum) was placed in a sterile 20 mm x 150 mm tube, and the tube was equilibrated in a 20 0 C water bath. The tube of disinfectant was inoculated with 100 ⁇ l of the test organism suspension at time zero. After 15 seconds, 1 ml of the organism/disinfectant suspension was removed to 9 ml of neutralizer. After 2 minutes, the neutralized suspension was serially diluted (1 :1x10, 1 :1x10 2 , 1:1x10 3 , etc.) in physiological saline solution (PSS).
  • PSS physiological saline solution
  • the number of viable organisms in selected dilution tubes was assayed by membrane filtration.
  • One (1) ml aliquots were plated in duplicate, and the membranes were washed with about 100 ml of sterile PSS and removed to Columbia agar plates. The plates were incubated at 37°C for 20 hours. The number of colonies on each filter was counted and log reduction and percent kill values were computed.
  • a titer (or measurement of the amount or concentration of a substance in a solution) of the test suspension was computed by performing membrane filtration assays of selected 1:10 dilutions of the test suspension in PSS.
  • a neutralizer control was performed by inoculating a mixture of 9 ml of neutralizer and 1 ml of disinfectant with 100 ⁇ l of the 1 : 10 5 dilution of the titer. This produced about 1 ,500 CFU/ml in the tube, which was allowed to stand for 20 minutes prior to dilution and assay of the tubes by membrane filtration using duplicate 1 ml samples. Sterilization controls were performed by filtering 100 ml (PSS) or 1 ml (other fluids) samples of each solution used in this testing. Plates were incubated as above.
  • PSS 100 ml
  • 1 ml other fluids
  • Sterilization controls indicated zero growth for the neutralizer, water, PSS, Columbia agar, disinfectant, and horse serum.
  • Results of the titer showed a viable staphylococcus concentration of 1x10 10 organisms per ml in the original suspension. Inoculation of 9.9 ml of disinfectant with 100 ⁇ l of this suspension produced an initial concentration of 1xlO 8 organisms per ml in the assay tube.
  • the disinfectant solution tested here had high antimicrobial activity against Staphylococcus aureus. It is significant to note that this level of activity was achieved even though the disinfectant was premixed with an organic load consisting of 5 % v/v horse serum. An organic load (such as 5% v/v horse serum) will often adversely affect the antimicrobial action of disinfectants.
  • the solution of Example 1 was nevertheless able to effect greater than a 7 log reduction of viable organisms within 15 seconds, even in the presence of 5% v/v horse serum.
  • Example 11 Kill-time studies of Bacillus subtilis using disinfectant of Example 6
  • test suspension containing endospores from ⁇ . subtilis was prepared from a culture grown for three days at 37°C in Leighton-Do ⁇ medium. The suspension was placed at 65 0 C for 30 minutes to kill vegetative organisms, and then centrifuged to pellet the spores. Spores were resuspended in sterile HPLC water and allowed to set overnight at 4 0 C. This washing/setting process was repeated a total of three times. The final spore suspension was examined for purity using phase-contrast microscopy and stored at 4 0 C until it was used.
  • a neutralizer was prepared that consisted of 9 ml tubes of 12.7 wt% Tween 80 (surfactant), 6.0 wt% Tamol, 1.7 wt% lecithin, 1 wt% peptone, and 1.0 wt% cystine and 500 mM Tris (pH 7.85), to which 100 ⁇ l of catalase solution (Sigma C100, 42,300/mg) was added immediately before use.
  • the "Kill Time” procedure followed was as follows: A 9.9 ml aliquot of the disinfectant of Example 6 (containing 5% v/v horse serum) was placed in a sterile 50 ml polypropylene centrifuge tube, and the tube was equilibrated in a 20 0 C water bath. The tube of disinfectant was inoculated with 100 ⁇ l of the spore/disinfectant suspension at time zero. After 60 seconds, 1 ml of the spore/disinfectant suspension was removed to 9.1 ml of neutralizer. After 2 minutes, the neutralized suspension was serially diluted (1 :1x10, 1:1x10 2 , 1:1x10 3 , etc.) in physiological saline solution (PSS).
  • PSS physiological saline solution
  • the number of viable spores in selected dilution tubes was assayed by membrane filtration.
  • One (1) ml aliquots were plated in duplicate, and the membranes were washed with about 100 ml of sterile PSS and removed to Columbia agar plates. The plates were incubated at 37°C for 20 hours. The number of colonies on each filter was counted and log reduction and percent kill values were computed.
  • a titer (or measurement of the amount or concentration of a substance in a solution) of the test suspension was computed by performing membrane filtration assays of selected 1:10 dilutions of the test suspension in PSS.
  • a neutralizer control was performed by inoculating a mixture of 9.1 ml of neutralizer and 1 ml of disinfectant with 100 ⁇ l of the 1:10 6 dilution of the titer. This produced about 96 CFU/ml in the tube, which was allowed to stand for 20 minutes prior to dilution and assay of the tubes by membrane filtration using duplicate 1 ml samples.
  • Sterilization controls were performed by filtering 100 ml (PSS) or 1 ml (other fluids) samples of each solution used in this testing. Plates were incubated as above.
  • the neutralization control data indicated that the test solution was adequately neutralized. Observed counts were similar to, or higher than those expected, indicating no residual killing took place due to un-neutralized disinfectant.
  • the disinfectant solution of Example 6 had good sporicidal activity, effecting a 1.38 log reduction within 3 minutes and greater than 7 log reduction in 10 minutes. It is worth noting that ⁇ . subtilis is a common species used in sporicidal testing and belongs to the same genus as the organism that causes anthrax. Because of their similarities, B. subtilis spores have been used as nonpathogenic surrogates for spores of Bacillus anthracis.
  • Example 12 Kill-time studies of Mycobacterium bovis using the disinfectant solution of Example 5
  • the suspension was thawed and mixed with an equal volume of phosphate-buffered gelatin solution in a Teflon-on-glass tissue grinder on ice.
  • the suspension was homogenized for two minutes, then diluted 1 :4 in physiological saline solution (PSS) containing 0.1% Tween 80.
  • PSS physiological saline solution
  • the suspension was vortexed and held on ice until used in inoculate the test surface.
  • a neutralizer mixture consisted of 50 ml flasks of Tryptic soy broth containing 1.0% Tween 80, 1.0% lecithin, and 50 ⁇ l of concentrated cataiase solution (Sigma, C100, 42,300 units/mg).
  • the CRA environmental Wipe Method which was used is detailed below.
  • An 8 x 12 inch piece of laminated plastic counter covering was secured to polypropylene dental trays (size B, Zi re Dental) with silicone adhesive. Lids and trays were sterilized by a hydrogen peroxide gas plasma sterilizer.
  • Two ml of test organism suspension was applied to the surface with a sterile2 x 2-in cotton-filled gauze sponge. The surface was allowed to dry 20-30 minutes in a biosafety cabinet under laminar flow. Then 3.5 ml of disinfectant (or water) was applied to a sterile gauze sponge, which was used to wipe the inoculated test surface for 10 seconds using about 150-g pressure with overlapping strokes (20 left to right, followed by 20 top to bottom).
  • the trays were flooded with 50 ml of neutralizer and scrubbed for 1 minute with a sterile polypropylene brush to remove and suspend organisms.
  • the fluid was collected and serially diluted 1:10 in physiological saline solution (PSS).
  • PSS physiological saline solution
  • the number of viable organisms in selected dilution tubes was assayed by membrane filtration. One ml aliquots were plated in duplicate. The membranes were washed with about 100 ml of sterile PSS and removed to Mycobacteria 7H11 agar plates. The plates were incubated at 37 0 C for about three weeks. The number of colonies on each was counted and log reduction and percent kill values were computed.
  • a titer of the test suspension was computed by performing membrane filtration assays of selected 1 :10 dilutions of the test suspension in PSS.
  • a neutralizer control was performed by inoculating a mixture of 9 ml of neutralizer and 1 ml of disinfectant with 100 ⁇ l of the 1:10 3 dilution of the titer containing 1750 CFU. This produced 175 CFU/ml in the tube, which was allowed to stand for 20 minutes prior to dilution and assay of the tubes by membrane filtration using duplicate 1 ml samples.
  • test suspension containing endospores from Bacillus subtilis was prepared from a culture grown for three days at 37 0 C in Leighton- Doi medium. The suspension was placed at 65 0 C for 30 minutes to kill vegetative organisms, then centrifuged to pellet the spores. Spores were resuspended in sterile HPLC water and allowed to set overnight at 4 0 C. This washing/setting process was repeated a total of three times. The final spore suspension was examined for purity using phase-contrast microscopy and stored at 4 0 C until used.
  • a neutralizer solution was also prepared that consisted of 9 ml tubes of 12.7 wt% Tween 80, 6.0 wt% Tamol, 1.7 wt% lecithin, 1 wt% peptone, and 1.0 wt% cystine, and 500 mM tris (pH 7.85), to which 100 ⁇ l of catalase solution (Sigma, C100, 42,300 u ⁇ its/mg) was added immediately before use.
  • the "kill time" procedure was as follows: A 9.9 ml aliquot of the disinfectant was placed in a 50 ml polypropylene sterile centrifuge tube. The tube was equilibrated in a 20 0 C water bath. The tube of disinfectant was inoculated with 100 ⁇ l of the spore suspension at time zero. After a 30 second contact time, one ml of spore/disinfectant suspension was removed to 9.1 ml of neutralizer. The tubes were mixed thoroughly. After 2 minutes, the neutralized suspension was serially diluted 1:10, in physiological saline solution in physiological saline solution (PSS). The number of viable spores in selected dilution tubes was assayed by membrane filtration.
  • PSS physiological saline solution
  • a titer of the test suspension was computed by performing membrane filtration assays on selected 1 :10 dilutions in PSS of the test suspension.
  • a neutralizer control was performed by inoculating a mixture of 9.1 ml of neutralizer and 1 ml of disinfectant with 100 ⁇ l of the 1:1x10 6 dilution of the titer. This produced about 130 CFU/ml in the tube, which was allowed to stand for 20 minutes prior to dilution and assay by membrane filtration using duplicate 1 ml samples.
  • Glutaraldehyde disinfectant solution is a common disinfectant used in hospitals to kill bacteria and other pathogens that might otherwise be difficult to kill. This study was carried out by performing a standard kill-time suspension test using a suspension of B. subtilis endospores. A 15 minute contact time was evaluated.
  • test suspension containing endospores from Bacillus subtilis was prepared from a culture grown on Nutrient agar, to which additional sporulation enhancements were added. Plates were harvested with sterile water and endospores were purified by repeated centrifugations and resuspensions in water. The final wash was in 70 wt% ethanol for 30 minutes, to ensure the death of all vegetative bacteria. The spores were resuspended in water containing 0.1 wt% Tween 80 to prevent clumping and stored at 4°C until used.
  • a neutralizer was prepared that consisted of 1 ml of freshly made, filter-sterilized sodium bisulfite solution at 5.28 wt%.
  • the "kill time" procedure was as follows: A 9.9 ml aliquot of the disinfectant was placed in a sterile glass culture tube. The tube was equilibrated in a 20 0 C water bath. The tube of disinfectant, 9 ml of 2.4 wt% alkaline glutaraldehyde (Freshly activated CIDEXPLUS, 3.4 %, Lot #:2002247TP - diluted to 2.4 wt% with sterile water), was inoculated with 100 ⁇ l of the test organism suspension at time zero. After 15 min, 1 ml of spore/disinfectant suspension was removed to 9 ml of neutralizer. The tube was mixed thoroughly.
  • the neutralized suspension was serially diluted (1 :1x10, 1 :1x10 2 , 1 :1x10 3 , etc.) in physiological saline solution (PSS).
  • PSS physiological saline solution
  • the number of viable spores in selected dilution tubes was assayed by membrane filtration. One (1) ml aliquots were plated in duplicate. The membranes were washed with about 100 ml of sterile PSS and removed to Columbia agar plates. The plates were incubated at 37°C for 20 hours. The number of colonies on each filter was counted and log reduction and percent kill values were computed.
  • a titer of the test suspension was computed by performing membrane filtration assays on selected 1 :10 dilutions in PSS of the test suspension.
  • a neutralizer control was performed by inoculating a mixture of 1 ml of neutralizer and 1 ml of disinfectant with 100 ⁇ l of the 1 :1x10 5 dilution of the titer. This produced about 450 CFU/ml in the tube, which was allowed to stand for 20 minutes prior to dilution and assay by membrane filtration using duplicate 1 ml samples.
  • Sterilization controls indicated zero growth for the glutaraldehyde, sodium bisulfite, water, PSS, and Columbia agar. Results of the titer showed a viable B. subtilis spore concentration of 9.45 x 10 8 spores per ml in the original suspension. Inoculation of 9.9 ml of disinfectant with 100 ⁇ l of this suspension produced an initial concentration of 9.45 x 10 6 spores per ml in the assay tube.
  • Neutralization control data revealed that the neutralizer was able to adequately neutralize this disinfectant. Observed counts were greater than those expected.
  • the 2.4 wt% alkaline glutaraldehyde solution tested had relatively slow sporicidal activity, producing only a 0.48 log-reduction in 15 minutes, which is significantly lower than that produced by any of the exemplary compositions above prepared in accordance with embodiments of the present invention.
  • a test suspension containing Mycobacterium bovis (ATCC # 35743) was prepared from a frozen suspension of a standardized culture grown in modified Proskauer-Beck medium. The suspension was thawed and mixed with an equal volume of phosphate-buffered gelatin solution in a Teflon-on-glass tissue grinder on ice. The suspension was homogenized for two minutes, then diluted 1:4 in physiological saline solution (PSS) containing 0.1% Tween 80. The suspension was vortexed and held on ice until used in inoculate the test surface.
  • PSS physiological saline solution
  • a neutralizer mixture consisted of 50 ml flasks of Tryptic soy broth containing 1.0% Tween 80, 1.0% lecithin, and 50 ⁇ l of concentrated catalase solution (Sigma, C100, 42,300 units/mg).
  • the CRA environmental Wipe Method which was used is detailed below.
  • An 8 x 12 inch piece of laminated plastic counter covering was secured to polypropylene dental trays (size B 1 Zirc Dental) with silicone adhesive. Lids and trays were sterilized by a hydrogen peroxide gas plasma sterilizer.
  • Two ml of test organism suspension was applied to the surface with a sterile2 x 2-in cotton-filled gauze sponge. The surface was allowed to dry 20-30 minutes in a biosafety cabinet under laminar flow. Then 3.5 ml of disinfectant (or water) was applied to a sterile gauze sponge, which was used to wipe the inoculated test surface for 10 seconds using about 150-g pressure with overlapping strokes (20 left to right, followed by 20 top to bottom).
  • the trays were flooded with 50 ml of neutralizer and scrubbed for 1 minute with a sterile polypropylene brush to remove and suspend organisms.
  • the fluid was collected and serially diluted 1:10 in physiological saline solution (PSS).
  • PSS physiological saline solution
  • the number of viable organisms in selected dilution tubes was assayed by membrane filtration. One ml aliquots were plated in duplicate. The membranes were washed with about 100 ml of sterile PSS and removed to Mycobacteria 7H11 agar plates. The plates were incubated at 37 0 C for about three weeks. The number of colonies on each was counted and log reduction and percent kill values were computed.
  • a titer of the test suspension was computed by performing membrane filtration assays of selected 1:10 dilutions of the test suspension in PSS.
  • a neutralizer control was performed by inoculating a mixture of 9 ml of neutralizer and 1 ml of disinfectant with 100 ⁇ l of the 1 :10 3 dilution of the titer containing 1750 CFU. This produced 175 CFU/ml in the tube, which was allowed to stand for 20 minutes prior to dilution and assay of the tubes by membrane filtration using duplicate 1 ml samples.
  • results of the titer showed the initial concentration of M. bovis was 1.75 x 107 CFU per ml in the prepared suspension, lnnoculation of the test surface following drying proceduced a challenge exhibited by the water control.
  • the initial concentration of viable bacilli on the test surface (So) was 2.63 x 10 5 .
  • a composition comprising 0.5% by weight of hydrogen peroxide, 8% by weight ethanol, and the balance of water containing 300 ppm of a colloidal silver was prepared.
  • a similar composition was prepared using identical components except that aqueous solution contained a silver alloy admixture with manganese (approximately 300 ppm silver and about 7 ppm manganese).
  • a kill test was performed resulting in a 0.13 log reduction or a 25.6% kill rate of the B. subtilis after 30 seconds using the colloidal silver composition.
  • the kill study was also performed using the colloidal silver- manganese alloy composition, which resulted in a 0.24 log reduction or 42.6% kill after 30 seconds.
  • a surface contaminated with nitrogen mustard gas is at least partially decontaminated composition of Example 5. Specifically, the composition of Example 5 is sprayed on the contaminated surface and is allowed to stand for about 15 minutes. The nitrogen mustard gas is oxidized and degraded into an amine oxide. Similar results can be achieved by oxidizing other chemical agents.
  • Example 18 Aqueous compositions usable for treatment or prevention of disease or other infection
  • An aqueous composition is prepared which includes 0.1 wt% hydrogen peroxide, 4 wt% glycerol, 600 ppm of silver-copper alloy, and the balance water.
  • the aqueous composition is effective in treating/preventing bacterial infections, treating/preventing viral infections, as well as for treating cancerous tissue.
  • Example 19 Aqueous compositions usable for treatment or prevention of disease or other infection
  • An aqueous composition is prepare which includes 0.05 wt% peracetic acid, 15 wt% ethanol, 300 ppm of colloidal silver, and the balance water.
  • the aqueous composition is effective in treating/preventing bacterial infections, treating/preventing viral infections, as well as for treating cancerous tissue.
  • Example 20 Aqueous compositions usable for treatment or prevention of disease or other infection
  • An aqueous composition is prepared which includes 0.5 wt% peracetic acid, 15 wt% ethanol, 300 ppm of colloidal silver, and the balance water.
  • the aqueous composition is effective in treating/preventing bacterial infections, treating/preventing viral infections, as well as for treating cancerous tissue.
  • An aqueous composition is prepared which includes 0.05 wt% hydrogen peroxide acid, 8 wt% ethanol, 150 ppm of colloidal silver, and the balance water.
  • the aqueous composition is effective in treating/preventing bacterial infections, treating/preventing viral infections, as well as for treating cancerous tissue.
  • Example 22 Aqueous compositions usable for treatment or prevention of disease or other infection
  • An aqueous composition is prepared which includes 0.05 wt% hydrogen peroxide acid, 150 ppm of colloidal silver, and the balance water.
  • the aqueous composition is effective in treating/preventing bacterial infections, treating/preventing viral infections, as well as for treating cancerous tissue.
  • Example 23 Aqueous compositions usable for treatment or prevention of disease or other infection
  • An aqueous composition is prepared with includes 0.05 wt% hydrogen peroxide acid, 0.2 wt% peracetic acid, 400 ppm of colloidal silver, and the balance water.
  • the aqueous composition is effective in treating/preventing bacterial infections, treating/preventing viral infections, as well as for treating cancerous tissue.
  • Example 24 Treatment of skin tumors by intra-lesional injection
  • a rabbit is afflicted with skin tumors.
  • a therapeutic aqueous composition is prepared which has 0.05 wt% hydrogen peroxide, 50 ppm colloidal silver, and the balance water.
  • the rabbit's tumors are injected intra-lesionally with 0.5 ml of the aqueous composition one time.
  • One week after injection with the aqueous composition the rabbit's tumors are measurably smaller.
  • Example 25 Treatment of skin tumors by intra-lesional injection
  • Example 26 Treatment of strep throat infection
  • An aqueous composition is prepared which contains 75 ppm colloidal silver, 1 wt% ethanol, 0.4 wt% percitric acid, and the balance water.
  • a subject diagnosed with a strep throat infection gargles and then swallows 1-10 ml of the prepared aqueous composition once every other days for 5 days (3 administrations). Within a day after the 3 administration the strep throat infection is resolved.
  • Example 27 Treatment of dog afflicted with the parvo virus
  • An aqueous composition is prepared which contains 10-100 ppm colloidal silver, 0.05 wt% hydrogen peroxide, and the balance water.
  • a dog afflicted with the Parvo virus receives 8 evenly spaced oral doses of 1-10 ml of the prepared aqueous composition over a 24 hour period. Within 24 hours of the final dose, the dog shows no effects or the infection.
  • Example 28 Treatment of a dog with advanced skin infection
  • An aqueous composition is prepared which contains 10 ppm colloidal silver 0.05 wt% hydrogen peroxide, and the balance water.
  • a dog suffering from an advanced skin infection which has caused rapid necrosis and the onset of kidney failure is treated. Due to the advanced necrosis of the skin, a veterinarian is forced to remove extensive portions of the dogs skin. The afflicted dog receives 1-10 ml/day of the aqueous composition orally, and further, is treated topically 3-4 times a day for 60 days. Within a period of 70 days, the infection is gone and the dog has regrown skin over removed areas without the need of skin grafts.
  • Example 29 Treatment of male infant afflicted with the papaloma virus
  • a therapeutic aqueous composition is prepared which contains 10 ppm silver, 0.05 wt% hydrogen peroxide, and the balance water.
  • a male infant afflicted with numerous wart patches on both hands who has previously been unsuccessfully treated with other therapeutic remedies receives an injection of the prepared aqueous composition.
  • the infant receives an injection of 0.5 ml of the prepared aqueous composition into one of the wart patches on his hand.
  • Example 30 Treatment of a burned tissue preventing bacterial growth
  • a therapeutic aqueous composition is prepared which contains 100 ppm silver, 0.5 wt% pe race tic acid, 6 wt% glycerol, and the balance water.
  • a subject with a third degree burn on the skin is treated with the prepared aqueous composition so as to prevent the onset of bacterial infection at the burned tissue site.
  • Example 31 Treatment of a herpes infection
  • a therapeutic aqueous composition which contains 80 ppm a colloidal silver-manganese alloy, 0.1 wt% hydrogen peroxide, 4 wt% ethanol, and the balance water.
  • a subject afflicted with a herpes infection with open sores receives topical treatment using the prepared aqueous composition.
  • the herpes infection is sprayed with the composition daily until the infection is healed.
  • Example 32 Treatment of a laceration preventing bacterial growth
  • a therapeutic aqueous composition which contains 600 ppm of ionic silver, 0.01 wt% hydrogen peroxide, 40 wt% ethanol, and the balance water.
  • a subject having a sever skin laceration which has become infected receives treatment using the prepared aqueous composition.
  • the composition is topically applied to the laceration once daily for 3 days to reduce or eliminate the bacterial infection.
  • Example 33 Treatment of a fungal infection
  • a therapeutic aqueous composition which contains 100 ppm of colloidal silver, 0.1 wt% hydrogen peroxide, 0.4 wt% peracetic acid, 3 wt% isopropyl alcohol, and the balance water.
  • a subject having a fungal infection of the feet is treated by topical application using the prepared aqueous composition. After a daily regimen of treatment for a period of about a week, the no sign of the fungus remains on the skin surface.

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Toxicology (AREA)
  • Business, Economics & Management (AREA)
  • Emergency Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)

Abstract

La présente invention concerne des procédés et des compositions destines à être utilisés pour la décontamination partielle ou totale de surfaces qui ont été contaminées par des agents chimiques ou biologiques de guerre ainsi que des procédés pour le traitement d'infections virales, d'infections bactériennes, d'infections fongiques, et de tissu cancéreux. L'invention concerne également l'utilisation d'une composition contenant un métal de transition peroxygénée. Selon un mode de réalisation, la composition comporte un excipient aqueux d'eau et entre 0,001% en poids et 40,0% en poids d'un composé peroxygéné. La composition peut comporter en outre de 0,001 ppm à 50,000 ppm en poids d'un métal de transition par rapport à la teneur en excipient aqueux. Éventuellement, un alcool peut être inclus dans la composition. Selon un mode de réalisation, le métal de transition peut être sous la forme d'un métal de transition colloïdal, tel que l'argent colloïdal.
PCT/US2007/018604 2006-08-24 2007-08-22 Procédés et compositions de décontamination et de traitement de maladie ou de lésion WO2008024422A2 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US11/510,133 2006-08-24
US11/510,133 US7504369B2 (en) 2005-02-25 2006-08-24 Methods and compositions for decontaminating surfaces exposed to chemical and/or biological warfare compounds
US11/514,722 US7553805B2 (en) 2005-02-25 2006-08-31 Methods and compositions for treating viral, fungal, and bacterial infections
US11/514,722 2006-08-31

Publications (2)

Publication Number Publication Date
WO2008024422A2 true WO2008024422A2 (fr) 2008-02-28
WO2008024422A3 WO2008024422A3 (fr) 2008-11-13

Family

ID=39107396

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2007/018604 WO2008024422A2 (fr) 2006-08-24 2007-08-22 Procédés et compositions de décontamination et de traitement de maladie ou de lésion

Country Status (1)

Country Link
WO (1) WO2008024422A2 (fr)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010132949A1 (fr) * 2009-05-22 2010-11-25 Saban Ventures Pty Limited Aerosol de decontamination
US9108854B2 (en) 2009-09-22 2015-08-18 Prebona Ab Biocidal colloidal dispersions of silica particles with silver ions adsorbed thereon
EP3134061A4 (fr) * 2014-04-21 2018-01-03 Aclaris Therapeutics, Inc. Formules de peroxyde et procédés et applicateurs pour leur utilisation
PL423355A1 (pl) * 2017-11-03 2019-05-06 Agnieszka Wolnicka Wodny preparat ze srebrem koloidalnym oraz zastosowanie preparatu do leczenia stanów dermatologicznych, w tym trądzika i grzybic
WO2019122429A1 (fr) 2017-12-21 2019-06-27 Prebona Ab Composition pharmaceutique comprenant une dispersion colloïdale et un agent thérapeutique, et procédés et utilisations de celle-ci
WO2020260643A1 (fr) 2019-06-26 2020-12-30 Prebona Ab Composition pharmaceutique comprenant une dispersion colloïdale et méthodes et utilisations associées

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2304104A (en) * 1938-12-10 1942-12-08 Du Pont Therapeutical zinc peroxide
US5563132A (en) * 1994-06-21 1996-10-08 Bodaness; Richard S. Two-step cancer treatment method
US20050256200A1 (en) * 2001-03-06 2005-11-17 Burkhart Craig G Benzoyl peroxide compositions having increased potency

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2304104A (en) * 1938-12-10 1942-12-08 Du Pont Therapeutical zinc peroxide
US5563132A (en) * 1994-06-21 1996-10-08 Bodaness; Richard S. Two-step cancer treatment method
US20050256200A1 (en) * 2001-03-06 2005-11-17 Burkhart Craig G Benzoyl peroxide compositions having increased potency

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010132949A1 (fr) * 2009-05-22 2010-11-25 Saban Ventures Pty Limited Aerosol de decontamination
US9108854B2 (en) 2009-09-22 2015-08-18 Prebona Ab Biocidal colloidal dispersions of silica particles with silver ions adsorbed thereon
EP3134061A4 (fr) * 2014-04-21 2018-01-03 Aclaris Therapeutics, Inc. Formules de peroxyde et procédés et applicateurs pour leur utilisation
US9980983B2 (en) 2014-04-21 2018-05-29 Aclaris Therapeutics, Inc. Peroxide formulations and methods and applicators for using the same
US10098910B2 (en) 2014-04-21 2018-10-16 Aclaris Therapeutics, Inc. Peroxide formulations and methods and applicators for using the same
US10493103B2 (en) 2014-04-21 2019-12-03 Aclaris Therapeutics, Inc. Peroxide formulations and methods and applicators for using the same
AU2015249841B2 (en) * 2014-04-21 2020-05-14 Aclaris Therapeutics, Inc. Peroxide formulations and methods and applicators for using the same
US10653721B2 (en) 2014-04-21 2020-05-19 Aclaris Therapeutics, Inc. Peroxide formulations and methods and applicators for using the same
US10729720B2 (en) 2014-04-21 2020-08-04 Aclaris Therapeutics, Inc. Peroxide formulations and methods and applicators for using the same
PL423355A1 (pl) * 2017-11-03 2019-05-06 Agnieszka Wolnicka Wodny preparat ze srebrem koloidalnym oraz zastosowanie preparatu do leczenia stanów dermatologicznych, w tym trądzika i grzybic
WO2019122429A1 (fr) 2017-12-21 2019-06-27 Prebona Ab Composition pharmaceutique comprenant une dispersion colloïdale et un agent thérapeutique, et procédés et utilisations de celle-ci
WO2020260643A1 (fr) 2019-06-26 2020-12-30 Prebona Ab Composition pharmaceutique comprenant une dispersion colloïdale et méthodes et utilisations associées

Also Published As

Publication number Publication date
WO2008024422A3 (fr) 2008-11-13

Similar Documents

Publication Publication Date Title
US7504369B2 (en) Methods and compositions for decontaminating surfaces exposed to chemical and/or biological warfare compounds
US7553805B2 (en) Methods and compositions for treating viral, fungal, and bacterial infections
AU2007290675B2 (en) Disinfectant systems and methods
US7351684B2 (en) Aqueous disinfectants and sterilants including colloidal transition metals
AU2007295050B9 (en) Aqueous sanitizers, disinfectants, and/or sterilants with low peroxygen content
US7507701B2 (en) Aqueous disinfectants and sterilants including transition metals
US7462590B2 (en) Aqueous disinfectants and sterilants comprising a peroxide/peracid/transition metal mixture
WO2008131226A2 (fr) Dispositifs, systèmes et procédés de distribution de solutions désinfectantes
US20100316534A1 (en) Air scrubbing system
WO2009032203A1 (fr) Agent d'assainissement de la peau contenant un métal colloïdal
WO2008024422A2 (fr) Procédés et compositions de décontamination et de traitement de maladie ou de lésion
US20120100040A1 (en) Composition for sterilizing surfaces
Mourad et al. Developing chlorine-based antiseptic by electrolysis
Stawarz-Janeczek et al. Disinfectants used in stomatology and SARS-CoV-2 infection
US20130137162A1 (en) Systems and methods for disinfecting medical instruments
RU2243152C2 (ru) Способ получения комплекса гексафторида ксенона с трифторидом бора и его использование
KR102660893B1 (ko) 항균 및 항바이러스 기능성 코팅 조성물과 그 제조방법
WO2022178649A1 (fr) Composition désinfectante et antiseptique, procédé de préparation de ladite composition et utilisation de celle-ci
McDonnell et al. Amsco® V-PRO™ 1: A new low temperature sterilisation system
Stawarz-Janeczek et al. Disinfectants Used in Stomatology and

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07837231

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

NENP Non-entry into the national phase

Ref country code: RU

122 Ep: pct application non-entry in european phase

Ref document number: 07837231

Country of ref document: EP

Kind code of ref document: A2